Integra Lifesciences Holdings Corp. (IART)
NASDAQ:IART
Want to see IART full AI Analyst Report?
IART Stock Chart & Stats
$11.14
-$0.23(-1.04%)
At close: 4:00 PM EST
$11.14
-$0.23(-1.04%)
Day’s Range― - ―
52-Week Range$8.70 - $16.49
Previous CloseN/A
Volume73.30K
Average Volume (3M)682.69K
Market Cap
$1.07B
Enterprise Value$2.89B
Total Cash (Recent Filing)$265.50M
Total Debt (Recent Filing)$2.04B
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Jul 29, 2026EPS Estimate
0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.48
Shares Outstanding77,796,906
10 Day Avg. Volume691,147
30 Day Avg. Volume682,692
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.91
Price to Sales (P/S)0.58
P/FCF Ratio-30.70
Enterprise Value/Market Cap2.69
Enterprise Value/Revenue1.75
Enterprise Value/Gross Profit3.30
Enterprise Value/Ebitda-10.54
Forecast
1Y Price Target
$18.80Price Target Upside68.76% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)2.35
Revenue Forecast (FY)$1.68B
Bulls Say, Bears Say
Bulls Say
Leadership And TurnaroundThere is potential for a multi-year turnaround under new leadership if regulatory issues are managed effectively.
Revenue PerformanceTotal revenues of $383 million were slightly above consensus of $381 million and within the midpoint of guidance.
Bears Say
Guidance And EstimatesThe company's estimates continue to have a downward bias, making it challenging to predict future performance accurately.
Operational ChallengesThe company is facing ongoing issues with shipholds and capacity, which are affecting its overall performance.
Regulatory And ComplianceThere is a cautious outlook on the company's shares due to concerns about structural damage from extended shipholds and compliance issues.
Integra Lifesciences News
IART FAQ
What was Integra Lifesciences Holdings Corp.’s price range in the past 12 months?
Integra Lifesciences Holdings Corp. lowest stock price was $8.70 and its highest was $16.49 in the past 12 months.
What is Integra Lifesciences Holdings Corp.’s market cap?
Integra Lifesciences Holdings Corp.’s market cap is $1.07B.
When is Integra Lifesciences Holdings Corp.’s upcoming earnings report date?
Integra Lifesciences Holdings Corp.’s upcoming earnings report date is Jul 29, 2026 which is in 76 days.
How were Integra Lifesciences Holdings Corp.’s earnings last quarter?
Integra Lifesciences Holdings Corp. released its earnings results on May 05, 2026. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.405 by $0.135.
Is Integra Lifesciences Holdings Corp. overvalued?
According to Wall Street analysts Integra Lifesciences Holdings Corp.’s price is currently Undervalued.
Does Integra Lifesciences Holdings Corp. pay dividends?
Integra Lifesciences Holdings Corp. does not currently pay dividends.
What is Integra Lifesciences Holdings Corp.’s EPS estimate?
Integra Lifesciences Holdings Corp.’s EPS estimate is 0.48.
How many shares outstanding does Integra Lifesciences Holdings Corp. have?
Integra Lifesciences Holdings Corp. has 77,796,906 shares outstanding.
What happened to Integra Lifesciences Holdings Corp.’s price movement after its last earnings report?
Integra Lifesciences Holdings Corp. reported an EPS of $0.54 in its last earnings report, beating expectations of $0.405. Following the earnings report the stock price went up 24.131%.
Which hedge fund is a major shareholder of Integra Lifesciences Holdings Corp.?
Currently, no hedge funds are holding shares in IART
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integra Lifesciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$18.80 (68.76% Upside)
$18.80 (68.76% Upside)
Blogger Sentiment
Bullish
IART Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 988.8K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.65%
12-Months-Change
Fundamentals
Return on Equity
-47.65%
Trailing 12-Months
Asset Growth
-11.72%
Trailing 12-Months
Company Description
Integra Lifesciences Holdings Corp.
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
IART Company Deck
IART Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear positive developments: a revenue and EPS beat in Q1, meaningful margin expansion, strong growth in Tissue Reconstruction (notably Integra Skin, DuraSorb and PriMatrix), improved operating cash flow, and decisive leadership and commercial alignment actions (CEO transition and new CCO). At the same time, the company faces notable challenges including pockets of organic decline in Specialty Surgery, ongoing remediation with some products off-market, negative free cash flow in the quarter, elevated net leverage (4.1x) and modest full-year organic growth guidance. Overall, the positives — operational improvements, margin gains, guidance maintained with a small EPS lift, and clear product/commercial catalysts (Braintree restart, SurgiMend relaunch, PMA pathway) — outweigh the near-term headwinds, though risks remain around product returns, cash conversion and leverage.View all IART earnings summariesIART Stock 12 Month Forecast
Average Price Target
$18.80
▲(68.76% Upside)
Technical Analysis
Ownership Overview
3.27% Insiders
30.39% Mutual Funds
2.01% Other Institutional Investors
36.72% Public Companies and
Individual Investors